MedDataX Logo

Non-Eosinophilic Biological Effects of IL-5

NCT ID: NCT06026202

Last Updated: 2023-10-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

5 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-01

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate the role of IL-5 in suppressing anti-viral immune responses in bronchial epithelial cells (BECs) and in peripheral blood mononuclear cells (PBMCs) from 5 people with asthma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phenotypic and Functional Characterization of Neutrophils and Eosinophils in Severe Asthma Treated With Biotherapy

NCT05972213

Asthma
RECRUITING

Molecular Mechanism of Asthma

NCT00180726

Asthma
WITHDRAWN NA

Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma

NCT04542902

Allergic Asthma Severe Eosinophilic Asthma
UNKNOWN NA

Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma

NCT04520165

Severe Asthma
ACTIVE_NOT_RECRUITING

Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma

NCT02559791

Severe Persistent Asthma Eosinophilic Bronchitis
COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

IL-5 has been shown to be present in higher levels in those with asthma, more so during viral infection. The investigators know from existing evidence that having increased levels of interferon (IFN) reduces asthma exacerbations and viral load. The investigators suspect that IL-5 reduces the immune response during viral infection in bronchial epithelial cells (BECs) and peripheral blood mononuclear cells (PBMCs) by reducing levels of IFN. The aim is to investigate if increased IL-5 in stable eosinophilic asthma and asthma exacerbations suppresses anti-viral immunity in bronchial epithelial cells and in peripheral blood mononuclear cells directly via IL-5 receptor signalling, suppressing rhinovirus induction of IFNs. The investigators also will evaluate if anti-IL-5 therapies suppress IL-5 concentrations in stable and exacerbated asthma in vivo and whether suppression of IL-5 in vivo restores deficient anti-viral immunity in BECs and PBMCs, thereby protecting against asthma exacerbations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Must be eligible for the study 'Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma' (MAELABA) (19SM5101).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Imperial College London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Imperial College London

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sebastian L Johnston, MBBS

Role: CONTACT

[email protected]
+44 20 7594 3764

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sebastian L Johnston, MBBS

Role: primary

[email protected]
+442075943764

Eva Fiorenzo, BMBS

Role: backup

[email protected]
+442075943751

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

326910

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lung Fluid and Peripheral Blood Neutrophil IL-5 Surface Receptor in Children With Asthma
NCT02866487 COMPLETED
Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
NCT04181190 COMPLETED
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
NCT00595491 RECRUITING PHASE1
A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma
NCT00659659 COMPLETED PHASE1
An Investigation of Tumor Necrosis Factor (TNF)-Alpha in Asthma Using Biopsy Explants and Primary Bronchial Epithelial Cell Cultures
NCT01161303 COMPLETED
The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)
NCT00292877 COMPLETED PHASE2
Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects
NCT06015256 RECRUITING NA
Flow Cytometry Analysis of Eosinophils in Severe Asthma Patients.
NCT05001529 UNKNOWN PHASE4
Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
NCT00725582 COMPLETED PHASE1
Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations
NCT05417906 ACTIVE_NOT_RECRUITING PHASE2
A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma
NCT00507130 COMPLETED PHASE2
Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
NCT00587288 COMPLETED PHASE2
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
NCT05528679 UNKNOWN PHASE2
Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma
NCT03610685 COMPLETED PHASE4
Effect of Benralizumab on Airway Remodeling in Asthma
NCT04365205 RECRUITING
Control of Asthma Patients Symptomatic on Inhaled Corticosteroids
NCT00330070 COMPLETED PHASE2
Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines
NCT04412044 COMPLETED PHASE4
A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma
NCT00783289 COMPLETED PHASE2
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
NCT00267202 COMPLETED PHASE4
The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma
NCT02249312 COMPLETED PHASE2
Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma
NCT01976208 COMPLETED PHASE2/PHASE3
A Sequential Dose-Escalation Study in Subjects With Mild Asthma
NCT00512486 COMPLETED PHASE1
Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues
NCT00603629 COMPLETED
Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
NCT02360072 COMPLETED
Study to Evaluate the Inflammatory Cells Activity in Patients With Persistent Asthma Treated With Montelukast (0476-403)(COMPLETED)
NCT00770900 COMPLETED PHASE4